Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine
Description
The coronavirus disease 2019 (COVID-19) pandemic imposes an urgent and continued need for the development of safe and cost-effective vaccines to induce preventive responses for limiting major outbreaks around the world. To combat severe acute
